Modeling calcific aortic valve disease with engineered human valve tissues identifies SAMHD1 as a therapeutic target¶

The finding¶

This paper reports the first engineered valvular tissues (EVTs) built from human iPSC-derived valvular interstitial cells in a 3D fibrinogen/Matrigel/collagen I hydrogel, assembled with hiPSC-derived cardiomyocytes to create a self-contracting, mechanically loaded valve model. Using time-series transcriptomics and WGCNA, the authors identify SAMHD1 as a core regulator of calcification, and show that recombinant SAMHD1 protein reduces calcification, restores tissue elasticity, and attenuates dysfunction under both static and cyclic mechanical stress.

Where it fits¶

This speaks directly to the mitochondrial/NLRP3 arm (Loop B) of the SAMHD1 p.A565T model — and, by extension, to the systemic vascular spectrum of SAMHD1 dysfunction. The paper demonstrates that SAMHD1 acts as a gatekeeper in valve calcification via an inflammatory pathway, which is consistent with the model's claim that reduced SAMHD1 function permits chronic innate-immune tone. The engineered myocardium-valve composite is particularly relevant: it validates that mechanical stress exacerbates calcification, a finding that maps onto the model's Loop C (paracrine/NF-κB/IFN-γ feedback), where tissue-scale mechanical and inflammatory signals converge. For the A565T variant specifically, this raises the possibility that partial loss of SAMHD1 function — sufficient to avoid Aicardi-Goutières syndrome but not to hold the system down — could contribute to a smoldering, non-acute inflammatory state in vascular tissues, with calcification as a downstream clinical outcome. The identification of SAMHD1 as a therapeutic target (rather than just a disease gene) aligns with the model's central claim that the loops are parallel and independently druggable.

Caveats¶

This is a wild-type SAMHD1 study in engineered tissues, not a study of the p.A565T heterozygous variant; the relevance to the specific hypomorphic allele is inferred, not demonstrated.
The model uses hiPSC-derived VICs, not primary patient cells, and the "inflammatory signal pathway" is identified via WGCNA correlation plus small-molecule inhibition — association, not direct mechanistic proof of SAMHD1's enzymatic role.
Recombinant SAMHD1 protein was added exogenously; the paper does not show whether this rescues via dNTPase activity, protein-protein interactions, or an off-target effect.

What to watch¶

Does recombinant SAMHD1 rescue calcification in the A565T heterozygous background, and does that rescue track with normalization of dNTP pools and NLRP3 licensing? If so, this engineered tissue platform could become the first scalable, mechanically active assay for screening SAMHD1-rescue therapies across the vascular spectrum.

Source: Modeling calcific aortic valve disease with engineered human valve tissues identifies SAMHD1 as a therapeutic target — 2026.